UroGen Pharma Ltd. — Director's Dealing 2020

Feb 24, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-02-20

Reporting Person: PFREUNDSCHUH PETER P. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-20	Ordinary Shares	M	1042	—	Acquired	6480	Direct
2020-02-20	Ordinary Shares	S	360	$29.68	Disposed	6120	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-20	Restricted Stock Units	$	M	1042	Disposed		Ordinary Shares (1042)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F2: This amount includes 1,000 shares reported on Reporting Person's Form 3 that were omitted from subsequent Form 4 filings.

F3: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F4: The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.